Kenvue Inc. (NYSE:KVUE) Stock Holdings Lifted by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. raised its position in shares of Kenvue Inc. (NYSE:KVUE) by 7.5% in the fourth quarter, Holdings Channel reports. The firm owned 272,497 shares of the company’s stock after buying an additional 19,042 shares during the period. Daiwa Securities Group Inc.’s holdings in Kenvue were worth $5,818,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Alerus Financial NA increased its holdings in Kenvue by 0.3% in the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after buying an additional 491 shares during the last quarter. Kiley Juergens Wealth Management LLC grew its position in Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after acquiring an additional 500 shares in the last quarter. Principle Wealth Partners LLC increased its stake in shares of Kenvue by 3.7% during the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after purchasing an additional 500 shares during the last quarter. White Pine Capital LLC raised its holdings in shares of Kenvue by 1.0% during the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after purchasing an additional 542 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its stake in shares of Kenvue by 29.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after purchasing an additional 568 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Down 1.7 %

Kenvue stock opened at $23.09 on Thursday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The business’s 50-day simple moving average is $21.77 and its 200-day simple moving average is $22.37. The firm has a market capitalization of $44.12 billion, a PE ratio of 43.56, a PEG ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.55%. Kenvue’s dividend payout ratio is 154.72%.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft cut Kenvue from a “buy” rating to a “hold” rating and reduced their price target for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. UBS Group reduced their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Barclays reduced their price target on Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Finally, Citigroup reduced their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Wednesday, January 15th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $23.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.